Second Annual Integrating Novel Agents With Radiotherapy

The CBCE (Center for Biomedical Continuing Education)
Ultima Vez Modificado: 4 de agosto del 2006

Share article


English

Conference Dates: November 4, 2006
Conference Location: Philadelphia, PA

Sponsoring Group: The CBCE (Center for Biomedical Continuing Education)

Conference Web Page URL: www.thecbce.om

Topics Covered: For many solid tumors, the treatment of choice is often surgical resection followed by radiation therapy, with or without chemotherapy, depending on the performance status of the patient. However, patient prognosis even after these interventions remains poor, and therapy is often accompanied by severe toxicity. More effective and less toxic therapies are needed. As the molecular details of tumor growth, angiogenesis, and progression become known, novel agents that target these pathways are being developed. These novel agents are being investigated as possible radiotherapy sensitizers, and clinical trials to date suggest a place for these agents in combined-modality treatment regimens for some solid tumors. This meeting will serve as a forum for opinion leaders to discuss emerging data on the appropriate use of targeted and cytotoxic therapies in combined-modality treatment regimens of solid tumors.

Conference Objectives: Please see www.thecbce.com for further information.

Who Should Attend: Medical oncologists, surgical oncologists, radiation oncologists, and other healthcare providers who have an interest in the biology, diagnosis, and treatment of cancer

Conference Agenda: Please see www.thecbce.com for further information

Registration Information: Please see www.thecbce.com for further information

Conference Fees: Please see www.thecbce.com for further information

Continuing Education: Yes

English
News
ASH: Novel Drug Beneficial in Multiple Myeloma

Aug 29, 2014 - In patients with relapsed or resistant multiple myeloma who have received up to three prior therapies excluding the first-generation proteasome inhibitor bortezomib, treatment with the second-generation proteasome inhibitor carfilzomib is associated a high response rate and a low incidence of side effects, according to research presented at the annual meeting of the American Society of Hematology, held from Dec. 5 to 8 in New Orleans.



I Wish You Knew

How cancer patients have changed my life

View More



Blogs and Web Chats

OncoLink Blogs give our readers a chance to react to and comment on key cancer news topics and provides a forum for OncoLink Experts and readers to share opinions and learn from each other.




OncoLink OncoPilot

Frente a un nuevo diagnóstico de cáncer o de cambiar el curso de su tratamiento actual? Deje que nuestro personal de enfermería cáncer que ayudan a pasar!

Más información